Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain

International Journal of Cancer

Volumn 78, Issue 3, 1998, Pages 372-376

  Rollenhagen, Christiane ^a   Chène, Patrick ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TETRAMER;

AMINO ACID SEQUENCE; ARTICLE; DNA BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN DOMAIN; SEQUENCE ANALYSIS;

AMINO ACID SUBSTITUTION; DIMERIZATION; EXONS; FEMALE; GENES, P53; HUMANS; MALE; MUTATION, MISSENSE; NEOPLASMS; PHENOTYPE; PROTEIN BIOSYNTHESIS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032578694     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981029)78:3<372::AID-IJC19>3.0.CO;2-8     Document Type: Article

References (33)

1. BARDEESY, N., FALKOFF, D., PETRUZZI, M.J., NOWAK, N., ZABEL, B., ADAM, M., AGUIAR, M.C., GRUNDY, P., SHOWS, T. and PELLETIER, J., Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature (Genet.), 7, 91-97 (1994).
2. CARIELLO, N.F., CUI, L., BEROUD, C. and SOUSSI, T., Database and software for the analysis of mutations in the human p53 gene. Cancer Res., 54, 4454-4460 (1994).
3. CARIELLO, N.F., DOUGLAS, G.R. and Soussi, T., Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. Nucl. Acids Res., 24, 119-120 (1996).
4. CHENE, P., MITTL, P. and GRÜTTER, M., In vitro structure-function analysis of the β-strand 326-333 of human p53. J. Mol. Biol., 273, 873-881 (1997).
5. CHI, S.G., DEVERE WHITE, R.W., MEYERS, F.J., SIDERS, D.B., LEE, F. and GUMERLOCK, P.H., p53 in prostate cancer: frequent expressed transition mutations. J. nat. Cancer Inst., 86, 926-933 (1994).
6. CHOU, P.Y. and FASMAN, G.D., Empirical predictions of protein conformation. Ann. Rev. Biochem., 47, 251-276 (1974).
7. CLORE, G.M., OMICHINSKI, J.G, SAKAGUCHI, K., ZAMBRANO, N., SAKAMOTO, H., APPELLA, E. and GRONENBORN, A.M., High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265, 386-391 (1994).
8. DILLER, L., KASSEL, J., NELSON, C.E., GRYKA, M.A., LITWAK, G., GEBHARDT, M., BRESSAC, B., OZTURK, M., BAKER, S., VOGELSTEIN, B. and FRIEND, S.H., p53 functions as a cell cycle control protein in osteosarcomas. Mol. cell. Biol., 10, 5772-5781 (1990).
9. DONEHOWER, L.A., HARVEY, M., SLAGLE, B.L., MCARTHUR, M.J., MONTGOMERY, C.A., BUTEL, J.C. and BRADLEY, A., Mice deficient for p53 are - developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356, 215-221 (1992).
10. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS. R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., Wafl, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
11. FAILLE, A., DE CREMOUX, P., EXTRA, J.M., LINARES, G., ESPIE. M., BOURSTYN, E., DE ROCQUANCOURT, A., GIACCHETTI, S., MARTY, M. and CALVO, F., 53 mutations in locally advanced breast cancers. Int. J. Cancer, 69, 145-150 (1994).
12. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C.C., p53 mutations in human cancers. Science, 253, 49-53 (1991).
13. HUPP, T.R., MEEK, D.W., MIDGLEY, C.A., and LANE, D.P., Regulation of the specific DNA binding function of p53. Cell, 71, 875-886 (1992).
14. ISHIOKA, C., ENGLERT, C., WINGE, P., YAN, Y.X., ENGELSTEIN, M. and FRIEND, S.H., Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene, 10, 1485-1492 (1995).
15. ISHIOKA, C., SHIMODAIRA, H., ENGLERT, C., SHIMADA, A., OSADA, M., JIA, L.Q., SUZUKI, T., GAMO, M. and KANAMARU, R., Oligomerisation is not essential for growth suppression by p53 in p53 deficient osteosarcoma Saos-2 cells. Biochem. Biophys. Res. Comm., 232, 54-60 (1997).
16. JEFFREY, P.D, GORINA, S. and PAVLETICH, N.P., Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science, 267, 1498-1502 (1995).
17. LANE, D.P., A death in the life of p53. Nature (Loud.), 358, 15-16 (1992).
18. LEE, W.L, HARWEY, T.S., YIN, Y., YAU, P., LITCHFIELD, D. and ARROWSMITH, C.H., Solution structure of the tetrameric minimum transforming domain of p53. Struct. Biol., 1, 877-890 (1994).
19. LEVINE, A.J., Wu, M.C., CHANG, A., SILVER, A., ATTIYEH, E.F., LIN, J. and EPSTEIN, C.B., The spectrum of mutations at the p53 locus. Ann. N. Y. Acad. Sci., 768, 111-128 (1995).
20. Liu, F.S., KOHLER, M.F., MARKS, J.R., BAST, R.C., BOYD, J. and BERCHUCK, A., Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet. Gvnecol., 83, 118-124 (1994).
21. LOMAX, ME., BARNES, D.M., GILCHRIST, R., VARLEY, J.M. and CAMPLE-JOHN, R.S., Two functional assays employed to detect an unusual mutation in the olisomerisation domain of p53 in a Li-Fraumeni like family. Oncogene, 14, 1869-1874 (1997).
22. MITTL., P.R.E., CHÈNE, P. and GRÜTTER, M.G., Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Cryst., D54, 86-89 (1998).
23. MIYAMOTO, H., KUBOTA, Y., SHUIN, T., TORIGOE, S., HOSAKA, M., IWASAKI, Y., DANENBERG, K. and DANENBERG, P.V., Analysis of p53 gene mutations in primary human bladder cancer. Oncol. Res., 5, 245-249 (1993).
24. NG, I.O.L., CHUNG, L.P., TSANG, S.W.Y., LAM, C.L., LAI, E.C.S., FAN, S.T. and NG, M., p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene, 9, 985-990 (1994).
25. NISHIDA, N., FUKUDA, Y., KOKURYU, H., TOGUCHIDA, J., YANDELL, D.W., IKENEGA, M., IMURA, H. and ISHIZAKI, K., Role and mutation al heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer. Res., 53, 368-372
26. SHAULIAN, E., ZAUBERMAN, A., MILNER, J., DA VIES, E. and OREN, M., Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J., 14, 2789-2797 (1993).
27. SRIVASTAVA, S, Zou, Z.Q., PIROLLO, K., BLATTNER, W. and CHANG, E.H., Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature, 348, 747-749 (1990).
28. SUBLER, M.A., MARTIN, D.W. and DEB, S., Overlapping domains on the p53 protein regulate its transeriptional activation and repression functions. Oncogene, 9, 1351-1359 (1994).
29. 1 checkpoint defect of monomeric p53 proteins. Oncogene, 13, 589-598 (1996).
30. TARUNINA, M. and JENKINS, J.R., Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene, 8, 3165-3173 (1993).
31. VARLEY, J.M., MCGOWN, G., THORNCROFT, M., COCHRANE, S., MORRISON, P., WOLL, P., KELSEY, A.M., MITCHELL, E.L.D., BOYLE, J., BIRCH, J.M. and EVANS, D.G.R., A previously undescribed mutation within the tetramerization domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene, 12, 2437-2442 (1996).
32. VOJTESEK, B., BARTEK, J., MIDGLEY, C.A. and LANE, D.P., An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Meth., 151, 237-244 (1992).
33. WATERMAN, J.L.F., SHENK, J.L. and HALAZONETIS, T.D., The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J., 14, 512-519 (1995).